Startups

Paradromics

Austin, Texas · Oakland, California · Austin, Texas, United States

Private developer of the investigational Connexus high-data-rate implanted brain-computer interface for speech and device control. Has an Oakland machine-learning office. The July 2021 $20M financing was seed funding.

Founded 2015

Team

Amy KruseBoard Member

Helmy EltoukhyBoard Member

James BurrowsChief Operating Officer

Justin SmithChief Strategy Officer

Kurtis NishimuraChief Technology Officer

Lydia HancockVP of Quality and Regulatory Affairs

Matt AngleFounder and CEO

Matt MarinoExecutive VP of Finance

Scott WayGeneral Counsel

Sofi HoysalVP of People

Stephen RyuChief Medical Officer

Vikash GiljaChief Scientific Officer

William MarksChief Clinical Officer

Zia HuqueBoard Member

Investments

$—2025-02-12	NEOM Investment Fund
$33M2023-05-18	Prime Movers Lab, Dolby Family Ventures, Green Sands Equity, Westcott Investment Group
$20M2021-07-22	Prime Movers Lab, Westcott Investment Group, Dolby Family Ventures, Synergy Ventures, Pureland Global Venture, IT-Farm Corporation, Alpha Edison
$—Unknown date	Kaleida Capital

team@apexlogos.ai3 hours ago
BCI research snapshot, reviewed 2026-10-06. Company identity: Paradromics. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # Paradromics Research date: **2026-10-06**. Review material only; no adex data was modified. All linked sources and HTML image references were accessed on this date. ## Identity and operating status Private company, **Paradromics Inc.**, founded in 2015 according to its official timeline; Austin, Texas headquarters established in 2019, with an Oakland machine-learning office added in 2023. Develops the **Connexus** implanted high-data-rate BCI for speech/device control. Current timeline records first implantation in the Connect-One clinical study in 2026 and real-time speech progress. [Official timeline, offices and team](https://paradromics.com/company/) ## Audit of pasted BCI.INTEL entry | Pasted claim | Assessment | |---|---| | Austin HQ; Matt Angle CEO | Confirmed by official company page. | | $127M total | Not reconciled to an official, dated lifetime financing disclosure. Keep unverified. | | Connexus product | Confirmed. | | Ticker: Argo / +$20M.SeriesB | Unsupported product/stage naming: company’s July 2021 $20M is explicitly **seed**, not Series B; official product is Connexus. | | ACTIVE | Supported; investigational BCI development is not commercial device approval. | ## Company profile image Direct company logo: [SVG](https://paradromics.com/wp-content/themes/paradromics/img/logo.svg) from official company page `<img class="logo">`. Alternative company profile/banner: [Official OG image](https://paradromics.com/wp-content/uploads/2026/07/Paradromics-Brain-Computer-Interface-Platform-Company.png). Team image names were paired to the official role card, not inferred from filename. ## Founders and public team | Person | Role / relationship | Profile and role evidence | Direct profile image URL | |---|---|---|---| | Matt Angle, PhD | Current: Founder and CEO | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team1.png) | | James Burrows | Current: Chief Operating Officer | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team2.png) | | Vikash Gilja, PhD | Current: Chief Scientific Officer | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team3.png) | | Justin Smith | Current: Chief Strategy Officer | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team10.png) | | Stephen Ryu, MD | Current: Chief Medical Officer | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/Chief-Medical-Officer.png) | | Kurtis Nishimura,PhD | Current: Chief Technology Officer | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team6.png) | | Matt Marino | Current: Executive VP of Finance | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team7.png) | | Lydia Hancock | Current: VP of Quality and Regulatory Affairs | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team8.png) | | Sofi Hoysal | Current: VP of People | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team9.png) | | Scott Way | Current: General Counsel | [Official company team](https://paradromics.com/company/) | [PFP](https://paradromics.com/wp-content/uploads/2026/06/team11.png) | ## Investments and financing | Announced date | Type | Amount (USD) | Lead | Other named investors / funders | Evidence | |---|---|---:|---|---|---| | Before 2021-07-22 | Earlier private financing, aggregate | $10M as reported then | Not stated | Not exhaustively stated | [2021 company release](https://paradromics.com/news/paradromics-raises-20mm-in-seed-funding-led-by-prime-movers-lab-to-advance-brain-computer-interfaces/) | | 2021-07-22 | Seed equity | $20M | Prime Movers Lab | Westcott Investment Group; Dolby Family Ventures; Synergy Ventures; Pureland Global Venture; IT-Farm; Alpha Edison | Same 2021 release | | 2023-05-18 | Series A | $33M | Prime Movers Lab | Westcott Investment Group; Dolby Family Ventures; Green Sands Equity | [2023 company release](https://paradromics.com/news/paradromics-raises-33-million-in-funding-achieves-breakthrough-medical-device-designation-from-fda/) | | 2025-02-12 | NEOM strategic investment / partnership | Undisclosed | NEOM Investment Fund | Further participants not asserted here | [Company investment announcement](https://paradromics.com/news/neom-investment-fund-partners-with-paradromics-to-drive-innovation-in-neurotechnology-healthcare/) | **Non-dilutive support, separate:** 2021-07-22 release reports $15M historical NIH/DARPA support. [2021-10-14 company release](https://paradromics.com/news/paradromics-announces-nih-award-to-fund-translational-and-early-stage-clinical-research/) announces a $3.2M NIMH Phase II SBIR award. A later [company funding summary](https://paradromics.com/blog/bci-news/) reports $38M venture and $18M public funding for 2021. These historical aggregates differ from the July release and may incorporate later closings; do not stack them as new rounds or add SBIR twice. No acquisition or debt close verified. Pasted $127M may mix private investment, government awards and estimated deals; hold it. ## Existing adex match and review decision Already present as `Paradromics`. Enrich existing record after review. Do not import the Argo ticker product or rename seed financing Series B. Lifetime funding remains unresolved; retain individual primary-source deals only. Read-only `Org` lookup found the following records. The snapshot below records existing claims, **not verification of those claims**.